三级aa视频在线观看-三级国产-三级国产精品一区二区-三级国产三级在线-三级国产在线

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Innovation

Dedication, team work boost China's COVID-19 research

Xinhua | Updated: 2022-03-29 14:33
Share
Share - WeChat
Zhang Linqi, leading scientist in developing China's first approved COVID-19 antibody drug, demonstrates a model of protein on the surface of the novel coronavirus. [Photo provided to chinadaily.com.cn]

BEIJING -- Many clinicians have referred to a COVID-19 drug developed by Zhang Linqi as a "miracle medicine" after seeing their patients' lasting fever symptoms diminish quickly following an injection of the drug.

A virologist at China's Tsinghua University, Zhang led his team to create a cocktail therapy of monoclonal antibodies BRII-196 and BRII-198, which cut hospitalizations and deaths by 80 percent in human trials and appears to work well against all existing variants.

It took just 18 months for the Chinese drug to be developed and receive regulatory approval.

"In less than two years, we finished a job that would otherwise take at least 10 years," Zhang said.

His latest research uses a deep learning approach to help his team obtain antibodies that can neutralize the coronavirus and its variants at a faster pace.

Anti-COVID-19 research results from Chinese institutes, universities and enterprises have been published in international academic journals every two or three days since January. Chinese scientists are contributing their wisdom, experience and painstaking efforts to enhance the human capacity to cope with the deadly virus.

While the Academy of Military Medical Sciences presented an mRNA COVID-19 antibody that provided lasting immunity in mice, Fudan University created an adenovirus vaccine candidate designed to give dual protection against both COVID-19 and influenza viruses.

Researchers at the Chinese Academy of Sciences (CAS), China's top academic institute, are working on an inhalable antibody with low cost and large-scale production advantages, while pharmaceutical companies in Shanghai and Suzhou have commenced global trials of a co-developed oral drug for moderate and severe COVID-19 cases.

Speaking to press at the fifth session of the 13th National People's Congress earlier in March, Minister of Science and Technology Wang Zhigang said that China has had fruitful beginning to its development of COVID-19 vaccines and drugs, with several candidates being granted market approval or undergoing clinical trials.

"The more tools to tackle COVID-19 that science and technology can provide, the better our anti-pandemic measures can become," the minister said.

None of this progress has come easily. China's impressive pace of medical research is the result of the long-term hard work of Chinese scientists.

Wang Qihui is a CAS virologist. Since January 2020, when Wang first volunteered to work on COVID-19, she has been racing against the clock to find ways to defeat the virus.

Tasked with finding effective antibodies in a short time, Wang led her team to conduct experiments day and night. She once stayed in her laboratory for two weeks, sometimes forgetting food and sleep.

Five months after the initial outbreak of the novel coronavirus, her team announced that JS016, a COVID-19-neutralizing antibody that they had developed, could be administered to healthy people in clinical trials. In November last year, the antibody was granted emergency-use authorization in 15 countries, including the United States and several European countries.

Lots of sacrifices were made in this process. Right before the results of the COVID-19 antibody study came out, Wang Qihui experienced neurological deafness because of high stress, which led to temporary hearing loss in her left ear.

She was hospitalized for five days after a doctor warned her that, in the absence of timely treatment, she could develop permanently impaired hearing.

The scientist has since recovered and is determined to make greater contribution to the fight against the pandemic. She has resumed her COVID-19 research, working to develop a nasal spray antibody drug and an mRNA vaccine.

Wang Qihui attributes her achievements largely to her previous experience in the field of viral infectious diseases, such as Middle East Respiratory Syndrome (MERS) and the Zika virus.

Zhang Linqi and his team, like Wang, have used their determination and wealth of experience in responding to new pathogens to deal with the pandemic.

Zhang has devoted 30 years to the study of HIV-1 pathogenesis and vaccine development, and to emerging and re-emerging human viral pathogens such as MERS, Ebola and the Zika virus.

"The development of a treatment drug and a vaccine sounded lighting fast, even to me, but it benefited from years of research on antibody drugs and HIV vaccine development," Zhang said when asked how the COVID-19 antibody drug he developed was created so quickly.

Inspired by the "AIDS cocktail," a combination treatment of three or four different medicines for people with HIV/AIDS, Zhang and his team selected 206 monoclonal antibodies and whittled the number down to two, creating their COVID-19 cocktail therapy.

It has demonstrated an improved performance in resisting virus mutations and maintained longer activity in the human body compared to similar therapies consisting of only one antibody.

Xiamen University, which has also accumulated significant experience in vaccine development, is a major research force in the fight against COVID-19. It was also one of the first institutions to receive global virus research donations.

Emerging technologies are involved in COVID-19 research. Tech giant Baidu has licensed its mRNA sequencing algorithm to French vaccine maker Sanofi for use in the design of COVID-19 vaccines and therapeutic products. According to the Chinese company, the algorithm can accelerate the research.

Zhang also stressed that interdisciplinary collaboration is very important in his work. He collaborated with Tsinghua biologists to decipher the structure of the virus, and with Shenzhen clinicians to isolate monoclonal antibodies in convalescent patients. These partnerships accelerated the development of China's first COVID-19 antibody drug.

"Scientific research is to explore the unknown in blind zones. We scientists not only need strong hearts and big brains, but also partners to support us. Even if we fail, we are not alone, as there are many people supporting us," Zhang said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 成人午夜爽爽爽免费视频 | 一级黄色在线看 | 另类二区| 国产不卡视频在线播放 | 久久国产精品-国产精品 | 麻豆视传媒一区二区三区 | 国产成人午夜极速观看 | 制服中文字幕 | 国产成人精品视频在放 | 国产成人亚洲精品蜜芽影院 | 特黄特色大片免费视频大全 | 日韩久久久精品中文字幕 | 国产一级二级三级视频 | 国产午夜亚洲精品久久999 | 国内精品综合九九久久精品 | 中文字幕一区二区在线观看 | 国产亚洲欧美一区 | 亚洲欧美一区二区三区另类 | 黄色片在线免费观看视频 | 精品视频麻豆入口 | 华人在线视频 | 看片国产 | 可以免费看的毛片 | 欧美日韩黄色大片 | 国产女主播真实视频在线观看 | 深夜精品影院18以下勿进 | 婷婷精品视频 | 亚洲二区在线视频 | 最新国产精品视频 | 自拍 亚洲 欧美 | 黄色大片在线观看 | 女人被狂躁视频免费版 | 日本一级特黄毛片高清视频 | 精品美女视频在线观看2023 | 亚洲精品日韩专区在线观看 | 日韩在线一区视频 | 欧美在线观看一区二区 | 91高清国产视频 | 欧美成人免费tv在线播放 | 亚洲草逼 | 亚洲欧美v国产一区二区 |